# Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes

> **NCT01617824** · PHASE4 · COMPLETED · sponsor: **University of Padova** · enrollment: 45 (actual)

## Conditions studied

- Type 2 Diabetes
- Chronic Renal Failure

## Interventions

- **DRUG:** Linagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01617824
- **Lead sponsor:** University of Padova
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01617824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01617824, "Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01617824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*